Non-Invasive Preimplantation Genetic Screening for Aneuploidies and Clinical Outcomes in Egg Donation Patients
Non-invasive Preimplantation Genetic Screening (niPGTA) in Oocyte Donation Patients.
Instituto Bernabeu
164 participants
Feb 26, 2026
OBSERVATIONAL
Conditions
Summary
Preimplantation genetic testing for aneuploidies (PGT-A) is commonly used in IVF but requires embryo biopsy and shows limited benefit in egg donation cycles. Non-invasive PGT-A (niPGTA), based on the analysis of cell-free embryonic DNA in spent culture media, offers a promising biopsy-free alternative. This prospective, blinded study in egg donation cycles will evaluate whether niPGTA-detected aneuploidy is associated with implantation failure and pregnancy loss, assessing its potential clinical value as a non-invasive embryo selection tool.
Eligibility
Inclusion Criteria4
- Women between 18 and 50 years old who are oocyte recipients.
- Signed consent form
- Transfer of a single blastocyst-stage embryo
- Male with normal sperm FISH
Exclusion Criteria3
- Uterine malformations
- Abnormal karyotypes in either partner
- Failure to sign informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07364526